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There are few studies examining the association between homocysteine (Hcy) level and the risk of 
hypertension with consideration for folate and vitamin  B12 as related to Hcy level. We simultaneously 
examined the associations of plasma levels of Hcy, folate, and vitamin  B12, and dietary folate intake 
with the prevalence of hypertension. Participants included 1046 men and 1033 women (mean 
age ± standard deviation: 56.0 ± 8.9 years) in the Japan Multi‑Institutional Collaborative Cohort Study. 
Dietary folate intake was estimated using a validated food frequency questionnaire. Hypertension 
was defined based on measured blood pressure and use of antihypertensive medication. A total of 
734 participants (35.3%) had hypertension. Multivariate‑adjusted odds ratios of hypertension for 
the highest quartile group of Hcy were 2.36 (95% CI 1.41–3.96) in men and 1.86 (95% CI 1.11–3.11) 
in women, as compared with the lowest group (P for trend = 0.014 and 0.005, respectively). Dietary 
folate intake was not correlated with hypertension in both men and women (P for trend = 0.099 and 
0.703, respectively). Plasma vitamin  B12 was positively associated with hypertension only in women 
(P for trend = 0.027). Plasma Hcy level was positively linked with hypertension after controlling for 
covariates, including folate and vitamin  B12.
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Hypertension is a major public health concern  worldwide1, which is influenced by both genetic and environ-
mental  factors2. Epidemiological studies have revealed that multiple environmental factors are associated with 
hypertension, such as obesity, alcohol consumption, sodium intake, and physical  inactivity3–6. A better under-
standing of modifiable risk factors for hypertension is useful for early detection and prevention of hypertension, 
which contributes to reducing this disease and its associated complications.
Homocysteine (Hcy) is a non-proteinogenic α-amino acid produced by the demethylation of methionine. 
Hyperhomocysteinemia is known as an established risk factor for cardiovascular disease (CVD) and  stroke7,8. To 
date, attention has been focused on the fact that this adverse effect caused by hyperhomocysteinemia might be 
partially mediated by a positive association between Hcy levels and blood  pressure9. Increased plasma Hcy causes 
oxidative stress and endothelial dysfunction, which leads to vascular constriction, stiffness, and decrease in the 
vasodilation by nitric oxide, resulting in an increase in blood  pressure9–11. Some previous observational studies 
have demonstrated positive associations between Hcy levels and blood pressure or the risk of  hypertension12–15. 
However, other studies including large prospective cohort studies do not support these  associations16–21. Thus, 
the association between Hcy levels and risk of hypertension remains inconclusive. A recent meta-analysis of 
relevant randomized trials also revealed that folate supplementation is effective in reducing blood pressure and 
Hcy levels among patients with hypertension and  hyperhomocysteinemia22. In addition, observational studies 
showed that dietary folate intake and folate level in blood were inversely associated with  hypertension23–25. These 
findings suggest that it is important to consider dietary intake and plasma levels of folate typically involved in 
the metabolism of Hcy in relation to the association between Hcy levels and risk of hypertension. Interestingly, 
a previous study suggested that vitamin  B12 as related to Hcy metabolism is also inversely associated with blood 
 pressure26. Nevertheless, few studies have examined the association with these nutrients. It is also of interest to 
examine the hypothesis that folate and vitamin  B12 are independently associated with the risk of hypertension 
in a general population. The evidence for this hypothesis is weak, although these vitamins are essential in the 
metabolism of methionine and are major nutritional determinants of plasma Hcy  levels27. Furthermore, the 
association of Hcy with hypertension may be dependent on folate and/or vitamin  B12. Therefore, to consider 
these nutrients involved in Hcy metabolism in addition to Hcy itself should be important.
Thus, in the present study, we aimed to simultaneously examine the association of plasma levels of Hcy, folate, 
and vitamin  B12, and dietary folate intake with the prevalence of hypertension, after controlling for multiple 
confounding factors, using a relatively large sample size in a cross-sectional study conducted among a general 
Japanese population.
Methods
Participants. Participants in the present study were enrolled in the Japan Multi-Institutional Collaborative 
Cohort (J-MICC)  Study28. The J-MICC Study is a large cohort study in Japan, launched in 2005 to identify inter-
actions between genetic and lifestyle factors for lifestyle-related diseases, including any cancer. The details and 
rationale of the J-MICC Study have been described  elsewhere29. Briefly, participants completed a self-admin-
istered questionnaire on lifestyle and medical status, and then donated a peripheral blood sample during the 
baseline survey. The J-MICC Study enrolled residents in the community, health check examinees, and patients 
at a cancer hospital. All participants in the study provided their written informed consent. The study protocol 
was approved by the ethics committees of Nagoya University Graduate School of Medicine, Aichi Cancer Center, 
Chiba Cancer Center, Nagoya City University Graduate School of Medical Sciences, Shiga University of Medi-
cal Science, Kyoto Prefectural University of Medicine, Kyushu University Graduate School of Medical Sciences, 
Saga University Faculty of Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, 
Tokushima University Graduate School, and University of Shizuoka participating in the J-MICC Study. The pre-
sent study was conducted according to the principles expressed in the World Medical Association Declaration 
of Helsinki.
A total of 92,631 participants were recruited from 14 different areas throughout Japan between 2004 and 2014 
(the dataset used in the present study was fixed on February 15, 2019). Of the total population, 2845 participants 
in eight study areas underwent measurement of plasma concentrations of Hcy, folate, and vitamin  B12. Among 
the total, we excluded all participants from two areas (n = 763) because of no available data for blood pressure. 
We further excluded those with missing data for blood pressure and use of antihypertensive medication (n = 1 
and 2, respectively). Thus, the present study finally included 2079 individuals (1046 men and 1033 women) from 
six study areas (Okazaki, Shizuoka, Takashima, Kyoto, Saga, and Kagoshima) with complete data for the analysis.
Assessment of lifestyle factors, dietary folate intake, and blood pressure. We used a self-admin-
istered questionnaire that included the following demographic characteristics and lifestyle and medical factors: 
alcohol consumption, smoking status, education level, physical activity, self-reported psychological stress, sleep-
ing hours, family and personal medical history, current medication, and menstruation in women.
Physical activity was estimated as metabolic equivalent hours per day, based on the frequency and duration of 
daily and leisure time  activities30,31. Ethanol intake (g/day) was estimated for current drinkers (defined as those 
who consumed alcohol at least once a week during the last year), based on the reported consumption frequency 
and amount consumed per one time for six alcoholic beverages (Japanese sake, shochu, shochu-based cocktails, 
beer, whisky, and wine)32. Dietary folate and energy intakes were estimated using a validated short food frequency 
 questionnaire33–36; Spearman correlation coefficients between estimated intakes according to the questionnaire 
and 3-day weighed dietary records were 0.41 in men and 0.36 in women for folate, and 0.36 in men and 0.37 
in women for total energy. Dietary folate intake per day was adjusted for total energy intake using the nutrient 
density  method37, which computes the dietary folate intake per 1000 kcal of daily total energy intake. We did 
not consider the loss of dietary folate intake due to the cooking with heat for foods because of limited data. In 
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addition, this study did not include participants who reported folate supplement use, and thus we did not con-
sider folate supplementation in examining the associations.
Height and weight were measured directly on the day of the survey; body mass index (BMI) was calculated 
as weight in kilograms divided by the square of height in meters (kg/m2). Each participant’s blood pressure was 
measured by a nurse or trained staff during health checks, using an automated blood pressure measurement 
monitor, with the patient in a seated  position38.
Blood samples and measurements of plasma Hcy, folate, and vitamin  B12. Fasting peripheral 
blood was drawn from participants at health checks, which was collected in a 7-mL EDTA-2Na-containing 
vacuum tube for plasma. Plasma separated from whole blood by using a centrifuge was stored at approximately 
− 80 °C until analysis. Plasma concentration of Hcy was determined using high-performance liquid chromatog-
raphy. Concentrations of folate and vitamin  B12 were determined using chemiluminescent enzyme immunoas-
say. All measurements were conducted at SRL Co., Ltd., Hachioji, Japan.
Statistical analyses. Participant characteristics were presented as mean ± standard deviation (SD) for con-
tinuous variables and as number and proportion for categorical variables, according to quartiles of plasma Hcy 
level by sex. Differences in the mean or proportion between quartiles of Hcy level were tested using analysis of 
variance or the chi-squared test, respectively. Difference in the mean of Hcy level between those with hyperten-
sion and those without was tested using the Mann–Whitney U test. The Spearman correlation coefficient was 
calculated between plasma folate levels and energy-adjusted dietary folate intake. We performed all analyses 
stratified by sex, as Hcy levels differ greatly by  sex39.
Hypertension was defined according to any of the following criteria: systolic blood pressure ≥ 140 mmHg, 
diastolic blood pressure ≥ 90 mmHg, or use of antihypertensive  medication40,41. Crude, age-adjusted, and multi-
variate-adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for hypertension were estimated according 
to quartile levels of plasma Hcy, folate, and vitamin  B12, and dietary folate intake using unconditional logistic 
regression models. The multivariate-adjusted model included the following covariates: age (as a continuous vari-
able), alcohol consumption (never, former, current drinker who consumed < 23 g/day ethanol, current drinker 
who consumed ≥ 23 g/day ethanol), smoking status (never, former, current), education level (9, 10–15, ≥ 16 years), 
BMI (< 18.5, 18.5 to < 25.0, ≥ 25.0 kg/m2), physical activity (as a continuous variable), psychological stress (not 
at all, not much, a little, a lot), sleeping hours (< 6, 6 to < 8, ≥ 8 h), family history of parental hypertension (yes, 
no for both father and mother), medical history of diabetes mellitus (yes, no), medical history of dyslipidemia 
(yes, no), medical history of CVD (yes, no), medical history of stroke (yes, no), menstruation for women (pre-
menopausal, perimenopausal, postmenopausal), and study area (Okazaki, Shizuoka, Takashima, Kyoto, Saga, 
Kagoshima). In an additional multivariate-adjusted model, we further controlled for plasma concentrations of 
Hcy, folate, and vitamin  B12, and dietary folate intake each other (as a continuous variable, respectively). Par-
ticipants with missing data for covariates were included as additional categories in the analysis. The linear trend 
for risk was evaluated using a continuous variable for plasma levels of Hcy, folate, and vitamin  B12, and dietary 
folate intake, respectively.
A two-tailed P value of < 0.05 was considered statistically significant. All statistical analyses were performed 
using SAS 9.4M5, which runs on SAS University Edition (SAS Institute Inc., Cary, NC, USA).
Results
Baseline characteristics of 2079 study participants (1046 men and 1033 women) according to the quartiles of 
plasma Hcy level by sex are shown in Table 1. Mean age ± SD was 56.0 ± 8.9 years, and the proportion of men was 
50.3%. Current drinkers accounted for 79.6% of men and 34.8% of women. There was no difference in the mean of 
age among quartiles of Hcy level. Plasma Hcy concentration was inversely associated with plasma levels of folate 
and vitamin  B12, dietary folate intake (in men), and energy intake. Spearman correlation coefficients between 
plasma folate level and energy-adjusted dietary folate intake were 0.105 in men and 0.129 in women (P < 0.001, 
respectively). The distributions of alcohol consumption, education level, BMI, physical activity, psychological 
stress, sleeping hours, and family history of parental hypertension did not significantly differ among quartiles 
of Hcy level. Men with higher plasma Hcy levels were more likely to be current smokers; this association was 
not observed in women. There were no differences in the distribution of medical histories of diabetes mellitus, 
dyslipidemia, and CVD among quartiles of Hcy level, and that of stroke differed only in women. Differences in 
the distribution of study areas were observed among quartiles of Hcy level.
Table 2 presents the crude, age-adjusted and multivariate-adjusted ORs and 95% CIs for hypertension accord-
ing to quartile levels of plasma Hcy, folate, and vitamin  B12, and dietary folate intake. A total of 734 participants 
(404 men and 330 women, representing 35.3% of participants) had hypertension. Plasma Hcy level in those with 
hypertension was significantly higher than that in those without hypertension; the means ± SD (nmol/mL) were 
8.8 ± 3.2 and 8.3 ± 3.6, respectively (P < 0.001). Plasma Hcy level was positively and significantly associated with 
the prevalence of hypertension, after controlling for multiple covariates including plasma levels of folate and 
vitamin  B12, and dietary folate intake. The multivariate-adjusted ORs for the highest quartile group of plasma 
Hcy were 2.36 (95% CI 1.41–3.96) in men and 1.86 (95% CI 1.11–3.11) in women, as compared with the lowest 
group (P for trend = 0.014 and 0.005, respectively). Dietary folate intake was not correlated with hypertension 
in both men and women. The multivariate-adjusted OR for the highest quartile group of dietary folate intake 
was 0.65 (95% CI 0.41–1.05) in men and 0.93 (95% CI 0.58–1.51) in women, as compared with the lowest group 
(P for trend = 0.099 and 0.703, respectively). The multivariate-adjusted ORs for the second and highest quartile 
groups of plasma folate in men were significantly higher than unity; 2.22 (95% CI 1.40–3.51) and 1.98 (95% CI 
1.23–3.21), respectively, as compared with the lowest group (P for trend = 0.231). The linear trend, however, was 
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Table 1.  Participant characteristics according to quartiles (Q1–Q4) of plasma Hcy level, by sex. Hcy 
homocysteine, METs metabolic equivalents, SD standard deviation.
Characteristics
Men (n = 1046) Women (n = 1033)
Q1 Q2 Q3 Q4 P value Q1 Q2 Q3 Q4 P value
No. of participants 227 275 266 278 223 264 266 280
Age (years ± SD) 56.2 ± 8.9 56.5 ± 8.6 56.0 ± 8.9 54.9 ± 9.8 0.177 55.5 ± 8.9 55.5 ± 9.0 56.6 ± 8.2 56.9 ± 8.7 0.131
Alcohol consumption (n, %)
Never 41 (18.1) 39 (14.2) 47 (17.7) 65 (23.4) 0.177 137 (61.4) 159 (60.2) 175 (65.8) 191 (68.2) 0.164
Former 3 (1.3) 5 (1.8) 3 (1.1) 9 (3.2) 2 (0.9) 5 (1.9) 1 (0.4) 4 (1.4)
Current, < 23 g/day ethanol 83 (36.6) 108 (39.3) 109 (41.0) 98 (35.3) 76 (34.1) 94 (35.6) 79 (29.7) 71 (25.4)
Current, ≥ 23 g/day ethanol 100 (44.1) 122 (44.4) 107 (40.2) 106 (38.1) 8 (3.6) 6 (2.3) 11 (4.1) 14 (5.0)
Unknown 0 (0.0) 1 (0.4) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Smoking status (n, %)
Never 66 (29.1) 76 (27.6) 68 (25.6) 65 (23.4) 0.047 200 (89.7) 242 (91.7) 244 (91.7) 243 (86.8) 0.470
Former 111 (48.9) 128 (46.6) 123 (46.2) 114 (41.0) 8 (3.6) 10 (3.8) 8 (3.0) 13 (4.6)
Current 50 (22.0) 71 (25.8) 75 (28.2) 99 (35.6) 15 (6.7) 12 (4.6) 14 (5.3) 24 (8.6)
Education level (years, n, %)
≤ 9 30 (13.2) 34 (12.4) 41 (15.4) 41 (14.8) 0.494 40 (17.9) 48 (18.2) 51 (19.2) 62 (22.1) 0.971
10–15 125 (55.1) 162 (58.9) 135 (50.8) 161 (57.9) 167 (74.9) 194 (73.5) 194 (72.9) 200 (71.4)
 ≥ 16 68 (30.0) 78 (28.4) 85 (32.0) 74 (26.6) 14 (6.3) 20 (7.6) 18 (6.8) 16 (5.7)
Unknown 4 (1.8) 1 (0.4) 5 (1.9) 2 (0.7) 2 (0.9) 2 (0.8) 3 (1.1) 2 (0.7)
Body mass index (kg/m2, n, %)
< 18.5 8 (3.5) 7 (2.6) 5 (1.9) 6 (2.2) 0.776 16 (7.2) 18 (6.8) 15 (5.6) 20 (7.1) 0.110
18.5 to < 25.0 156 (68.7) 191 (69.5) 174 (65.4) 188 (67.6) 172 (77.1) 182 (68.9) 181 (68.1) 187 (66.8)
 ≥ 25.0 63 (27.8) 77 (28.0) 87 (32.7) 84 (30.2) 35 (15.7) 64 (24.2) 70 (26.3) 73 (26.1)
Physical activity (METs・hours/day, mean ± SD) 15.4 ± 15.4 15.7 ± 15.1 15.3 ± 15.4 13.0 ± 13.1 0.126 13.7 ± 12.7 13.1 ± 10.9 14.9 ± 12.9 14.5 ± 13.3 0.372
Psychological stress (n, %)
Not at all 13 (5.7) 20 (7.3) 19 (7.1) 20 (7.2) 0.788 5 (2.2) 17 (6.4) 11 (4.1) 10 (3.6) 0.212
Not much 66 (29.1) 83 (30.2) 76 (28.6) 68 (24.5) 36 (16.1) 43 (16.3) 57 (21.4) 55 (19.6)
A little 107 (47.1) 128 (46.6) 112 (42.1) 126 (45.3) 126 (56.5) 131 (49.6) 138 (51.9) 130 (46.4)
A lot 40 (17.6) 43 (15.6) 57 (21.4) 62 (22.3) 55 (24.7) 73 (27.7) 59 (22.2) 84 (30.0)
Unknown 1 (0.4) 1 (0.4) 2 (0.8) 2 (0.7) 1 (0.5) 0 (0.0) 1 (0.4) 1 (0.4)
Sleeping hours (hours/day, n, %)
< 6 15 (6.6) 24 (8.7) 23 (8.7) 34 (12.2) 0.072 28 (12.6) 33 (12.5) 31 (11.7) 40 (14.3) 0.569
6 to < 8 170 (74.9) 191 (69.5) 181 (68.1) 166 (59.7) 163 (73.1) 195 (73.9) 183 (68.8) 197 (70.4)
 ≥ 8 42 (18.5) 60 (21.8) 61 (22.9) 77 (27.7) 32 (14.4) 36 (13.6) 52 (19.6) 42 (15.0)
Unknown 0 (0.0) 0 (0.0) 1 (0.4) 1 (0.4) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.4)
Family history of hypertension (n, %)
Father 53 (23.4) 62 (22.6) 58 (21.8) 68 (24.5) 0.982 64 (28.7) 69 (26.1) 62 (23.3) 69 (24.6) 0.552
Mother 61 (26.9) 83 (30.2) 75 (28.2) 63 (22.7) 0.278 76 (34.1) 86 (32.6) 77 (29.0) 96 (34.3) 0.119
Medical history (n, %)
Diabetes mellitus 21 (9.3) 29 (10.6) 26 (9.8) 17 (6.1) 0.460 10 (4.5) 10 (3.8) 12 (4.5) 11 (3.9) 0.247
Dyslipidemia 33 (14.5) 50 (18.2) 52 (19.6) 38 (13.7) 0.361 39 (17.5) 50 (18.9) 41 (15.4) 59 (21.1) 0.336
Cardiovascular disease 6 (2.6) 10 (3.6) 14 (5.3) 6 (2.2) 0.384 6 (2.7) 3 (1.1) 5 (1.9) 12 (4.3) 0.184
Stroke 4 (1.8) 10 (3.6) 9 (3.4) 9 (3.2) 0.733 5 (2.2) 3 (1.1) 4 (1.5) 12 (4.3) 0.013
Plasma Hcy (nmol/mL, mean ± SD) 6.4 ± 0.7 8.0 ± 0.4 9.6 ± 0.5 13.9 ± 5.2 < 0.001 5.0 ± 0.5 6.2 ± 0.3 7.3 ± 0.4 10.1 ± 2.9 < 0.001
Plasma folate (ng/mL, mean ± SD) 9.5 ± 2.9 8.9 ± 2.1 8.2 ± 2.0 7.5 ± 1.3 < 0.001 11.3 ± 4.4 9.7 ± 2.2 9.3 ± 3.0 8.6 ± 2.0 < 0.001
Plasma vitamin B12 (pg/mL, mean ± SD) 940 ± 345 868 ± 238 815 ± 235 754 ± 324 < 0.001 1070 ± 502 945 ± 357 899 ± 335 801 ± 209 < 0.001
Dietary folate intake (μg/1000 kcal/day, 
mean ± SD) 172 ± 51 169 ± 58 163 ± 48 156 ± 54 0.004 239 ± 87 236 ± 80 241 ± 81 228 ± 69 0.238
Energy intake (kcal/day, mean ± SD) 2000 ± 363 1949 ± 360 1937 ± 357 1901 ± 368 0.024 1566 ± 246 1576 ± 241 1531 ± 246 1513 ± 251 0.010
Study area (n, %)
Okazaki 36 (15.9) 53 (19.3) 52 (19.6) 46 (16.6) < 0.001 34 (15.3) 55 (20.8) 45 (16.9) 43 (15.4) < 0.001
Shizuoka 102 (44.9) 101 (36.7) 74 (27.8) 61 (21.9) 45 (20.2) 42 (15.9) 30 (11.3) 17 (6.1)
Takashima 37 (16.3) 38 (13.8) 26 (9.8) 26 (9.4) 81 (36.3) 69 (26.1) 62 (23.3) 58 (20.7)
Kyoto 2 (0.9) 13 (4.7) 22 (8.3) 51 (18.4) 0 (0.0) 2 (0.8) 7 (2.6) 15 (5.4)
Saga 40 (17.6) 42 (15.3) 36 (13.5) 44 (15.8) 54 (24.2) 60 (22.7) 59 (22.2) 47 (16.8)
Kagoshima 10 (4.4) 28 (10.2) 56 (21.1) 50 (18.0) 9 (4.0) 36 (13.6) 63 (23.7) 100 (35.7)
5
Vol.:(0123456789)
Scientific Reports |        (2020) 10:18499  | https://doi.org/10.1038/s41598-020-75267-3
www.nature.com/scientificreports/
Men (n = 1046) Women (n = 1033)
Q1 Q2 Q3 Q4 P for trend Q1 Q2 Q3 Q4 P for trend
Hcy
Median (nmol/
mL) 6.6 8.0 9.4 12.4 5.2 6.2 7.4 9.3
Range 3.4–7.2 7.4–8.6 8.8–10.6 10.8–59.0 3.0–5.6 5.8–6.6 6.8–8.0 8.2–40.4
No. of partici-

















































































mL) 6.4 7.5 8.5 10.6 7.1 8.3 9.6 12.4
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not statistically significant. The corresponding ORs were not significant in women. Plasma vitamin  B12 level 
was positively associated with hypertension, especially in women. The multivariate-adjusted OR for the highest 
quartile group of plasma vitamin  B12 was 1.49 (95% CI 0.93–2.37), as compared with the lowest group (P for 
trend = 0.027).
Discussion
In the present study, we found that increased plasma Hcy level was significantly associated with the prevalence 
of hypertension in both men and women after controlling for multiple covariates including plasma levels of 
folate and vitamin  B12, and dietary folate intake. Dietary folate intake was not associated with the prevalence of 
hypertension in both men and women.
Our finding for the association between Hcy level and hypertension is consistent with those from previous 
cross-sectional  studies12–15. As a large previous cross-sectional study, the Third National Health and Nutrition 
Examination Survey in the United States demonstrated that those with the highest quintile group of plasma 
Hcy had a two- to three-fold OR of hypertension, in comparison with the lowest  group14, which is similar to 
our findings. In men, the multivariate-adjusted OR of hypertension for the highest quintile group (range for 
plasma Hcy concentration: 13.1–132 μmol/L) was 1.9 (95% CI 0.71–5.14) in comparison with the lowest group 
(3.3–7.5 μmol/L) (P for trend = 0.12). In women, the OR for the highest quintile group (11.0–118 μmol/L) was 
3.0 (95% CI 1.70–5.39) as compared with the lowest group (3.0–6.1 μmol/L) (P for trend = 0.0001).
There are several potential mechanisms by which increased plasma Hcy can cause hypertension. Hcy has been 
shown to be associated with oxidative stress, endothelial dysfunction, increased inflammation, and decreased 
bioavailability of endothelium-derived nitric oxide, resulting in increased blood  pressure9–11. Additionally, Hcy 
activates metalloproteinase and induces collagen synthesis, and causes imbalances of elastin/collagen ratio. Inter-
estingly, Hcy also promotes angiotensin-converting enzyme activity that may lead to upregulation of angiotensin 
II and subsequently  hypertension42. Nevertheless, several cross-sectional and large prospective studies showed no 
evidence for an association between Hcy level and hypertension, after controlling for confounding  factors16–21. 
The Mendelian randomization (MR) approach is a method of using the measured variation in genes to examine 
the causal effect of modifiable exposures for disease. The MR has recently been applied to evaluate this associa-
tion. In that study, Hcy was reported not to be a causal factor for blood  pressure43, suggesting that increased 
plasma Hcy may be concomitant with hypertension. However, the evidence from prospective studies and MR 
analysis is insufficient for this association; thus, further investigation will be needed to verify this relationship.
Although folate plays an important role in the metabolism of Hcy, limited data are available on the associa-
tion between plasma folate levels and dietary folate intake and the risk of hypertension. In the present study, 
dietary folate intake was not associated with the prevalence of hypertension, whereas the ORs of hypertension 
were significantly higher than unity for the second and highest quartiles of plasma folate in men. The reason for 
this discrepancy is unclear. Cross-sectional and prospective studies have shown an inverse association between 
serum folate level and blood  pressure23,24. In addition, two prospective studies have demonstrated that dietary 
folate intake is inversely associated with the incidence of  hypertension24,25. Our findings are inconsistent with 
these results. When we calculated the Spearman correlation coefficient between plasma folate level and energy-
adjusted dietary folate intake, the positive correlation appeared to be weak, which is similar to results from a 
previous study in  Japan44. The biological mechanisms for the weak correlation between plasma folate level and 
dietary folate intake remained unclear. Measuring folate intake with a questionnaire and the plasma folate assay 
are prone to a different type and magnitude of systematic or random errors.
It is possible that unknown confounders brought significantly high ORs of hypertension for the second and 
highest quartiles of plasma folate level in men, although we controlled for multiple confounders to evaluate 
this association. As the trend was not significant in men and we observed no clear association of either dietary 
Table 2.  The ORs and 95% CIs for hypertension according to quartile levels (Q1–Q4) of plasma Hcy, 
folate, and vitamin  B12, and dietary folate intake, by sex. CI confidence interval, Hcy homocysteine, OR 
odds ratio. a Adjusted for age (continuous variable), smoking status, alcohol consumption, education level, 
body mass index, physical activity (continuous variable), psychological stress, sleeping hours, family history 
of hypertension in father, family history of hypertension in mother, medical history (diabetes mellitus, 
dyslipidemia, cardiovascular disease, and stroke), total energy intake (continuous variable), menstruation 
status (women only), and study area. b Additionally adjusted for plasma levels of Hcy, folate, and vitamin  B12, 
and dietary folate intake each other.
Men (n = 1046) Women (n = 1033)
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intake or plasma levels of folate with hypertension in women, further studies are warranted to examine the role 
of plasma folate.
We also found no clear association between plasma vitamin  B12 levels and hypertension, although there 
was a positive correlation only in women. These results are consistent with those from a previous case–control 
 study45. Interestingly, a cross-sectional study showed that dietary vitamin  B12 intake is inversely associated with 
blood pressure among preschool  children26, suggesting that vitamin  B12 may play a role in reducing the risk of 
hypertension. However, we did not consider this issue owing to no available data for dietary vitamin  B12 intake. 
Further studies using data for both dietary intake and plasma levels of vitamin  B12 will elucidate the inconsistent 
associations with hypertension.
We found a significant positive association between Hcy level and the prevalence of hypertension, with 
consideration for folate and vitamin  B12 as related to Hcy level. It is meaningful that the strong positive associa-
tion remained even when controlling for dietary folate intake, and plasma levels of folate and vitamin  B12. The 
association may be independent of folate and vitamin  B12.
The strengths of the present study include its relatively large sample size, use of a validated FFQ for dietary 
folate and energy intake, and controlling for several confounders obtained from the self-administered ques-
tionnaire. Several potential limitations, however, should be mentioned. First, we were unable to determine the 
causal relationship between Hcy level and risk of hypertension because of the cross-sectional design of this 
study. Second, because most participants analyzed in the present study were Japanese, the generalizability of our 
findings to other populations remains to be explored. Third, although our FFQ was well validated using dietary 
 record33–36, the validity correlation coefficient for dietary folate intake was not so high, so that the dietary folate 
intake is a rough estimate to rank the participants. Fourth, we did not consider the loss of dietary folate intake 
due to the cooking with heat for foods because of limited data. Fifth, we did not examine the associations with 
consideration for folate supplement use because no participant reported its use in the present analysis. Lastly, 
we could not consider the genetic background of the included individuals in relation to the association with risk 
of hypertension because it requires too much analysis to be included in one study. Methylenetetrahydrofolate 
reductase (MTHFR) C677T (rs1801133) is one of the important polymorphisms strongly associated with Hcy 
levels in the human body, whose T allele significantly reduces MTHFR activity, resulting in increased plasma 
Hcy levels. However, this variant itself has been reported not to be associated with blood  pressure43. In addi-
tion, other genetic background regarding blood pressure appeared to be unrelated to Hcy levels in the present 
study because we observed no clear differences in family history of parental hypertension among the quartiles 
of plasma Hcy level, by sex.
In conclusion, we found a significant positive association between plasma Hcy levels and the prevalence of 
hypertension when considering plasma folate and vitamin  B12, and dietary folate intake typically involved in 
the metabolism of Hcy. Further studies are warranted to explore the causal inference for this association and to 
clarify the roles of folate and vitamin  B12 in the risk of hypertension as related to Hcy.
Data availability
The datasets generated during and/or analyzed during the current study are not publicly available due to ethical 
restriction but are available from the corresponding author on reasonable request.
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